and it was a researcher, the main researcher at amgen and it was glenn begley and he was head of cancerresearch for the strong company and he was, he went back to review a bunch of exciting studies that he had looked at as they came across the transom that had been published in the scientific journal and he discovered that when the originally came across his desk, he thought wow, if any of these were good results, i could get some really good deeds for drugs so he thought, you know, this is how pharmaceutical companies work by a large these days, that's a lot of their own basic research, they rely on science they said you know, i couldn't get these studies were the first time, we tried to replicate in our lab, let's try again so if you went to a second cycle of getting these studies replicate and 53 studies, he even recruited the help of a lot of the scientists who done the work to begin with and of those 53 only accident to replicate which is what, 11 percent so pretty grim statistics and he was raising the alarm saying a lot of the research coming out of academic labs is not reproduci